Strategic Global Advisors LLC cut its position in Pfizer, Inc. (NYSE:PFE) by 41.1% during the first quarter, according to its most recent disclosure with the SEC. The firm owned 109,220 shares of the biopharmaceutical company’s stock after selling 76,365 shares during the period. Pfizer makes up about 1.3% of Strategic Global Advisors LLC’s portfolio, making the stock its 16th largest position. Strategic Global Advisors LLC’s holdings in Pfizer were worth $3,736,000 as of its most recent filing with the SEC.

Other institutional investors have also added to or reduced their stakes in the company. Asset Planning Services Ltd. raised its stake in Pfizer by 4.9% in the first quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 137 shares during the period. Orrstown Financial Services Inc. raised its stake in Pfizer by 23.0% in the first quarter. Orrstown Financial Services Inc. now owns 3,275 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 612 shares during the period. Cable Hill Partners LLC raised its stake in Pfizer by 6.0% in the first quarter. Cable Hill Partners LLC now owns 4,664 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 265 shares during the period. D Orazio & Associates Inc. raised its stake in Pfizer by 0.5% in the fourth quarter. D Orazio & Associates Inc. now owns 5,223 shares of the biopharmaceutical company’s stock valued at $170,000 after buying an additional 28 shares during the period. Finally, Acropolis Investment Management LLC raised its stake in Pfizer by 1.9% in the first quarter. Acropolis Investment Management LLC now owns 5,251 shares of the biopharmaceutical company’s stock valued at $180,000 after buying an additional 100 shares during the period. 70.10% of the stock is owned by institutional investors.

Shares of Pfizer, Inc. (NYSE:PFE) remained flat at $33.28 on Wednesday. The company had a trading volume of 1,155,035 shares. Pfizer, Inc. has a 12-month low of $29.83 and a 12-month high of $35.38. The firm has a 50-day moving average price of $33.43 and a 200-day moving average price of $33.25. The company has a market cap of $198.61 billion, a price-to-earnings ratio of 24.35 and a beta of 1.00.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.02. The firm had revenue of $12.90 billion during the quarter, compared to analysts’ expectations of $13.08 billion. Pfizer had a net margin of 15.84% and a return on equity of 24.11%. Pfizer’s revenue for the quarter was down 1.9% on a year-over-year basis. During the same period in the previous year, the company earned $0.64 EPS. Equities analysts forecast that Pfizer, Inc. will post $2.56 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, September 1st. Shareholders of record on Friday, August 4th will be paid a $0.32 dividend. The ex-dividend date is Wednesday, August 2nd. This represents a $1.28 annualized dividend and a yield of 3.85%. Pfizer’s payout ratio is currently 94.12%.

COPYRIGHT VIOLATION NOTICE: “Strategic Global Advisors LLC Has $3.74 Million Stake in Pfizer, Inc. (PFE)” was originally published by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another publication, it was illegally copied and republished in violation of US & international trademark & copyright law. The original version of this story can be read at https://www.dailypolitical.com/2017/08/09/strategic-global-advisors-llc-has-3-74-million-stake-in-pfizer-inc-pfe.html.

Several research firms have commented on PFE. Jefferies Group LLC set a $35.00 price objective on Pfizer and gave the stock a “neutral” rating in a research note on Wednesday, August 2nd. Morgan Stanley reiterated a “neutral” rating and set a $35.00 price objective (down from $38.00) on shares of Pfizer in a research note on Monday, June 12th. Berenberg Bank set a $39.00 price objective on Pfizer and gave the stock a “neutral” rating in a research note on Tuesday, August 1st. Citigroup Inc. lowered Pfizer from a “neutral” rating to a “sell” rating and cut their price objective for the stock from $38.00 to $31.00 in a research note on Tuesday, May 16th. Finally, BMO Capital Markets reiterated a “hold” rating and set a $33.00 price objective on shares of Pfizer in a research note on Thursday, April 27th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $37.77.

In other Pfizer news, CEO Ian C. Read sold 96,950 shares of Pfizer stock in a transaction that occurred on Friday, August 4th. The shares were sold at an average price of $34.00, for a total value of $3,296,300.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.06% of the stock is currently owned by insiders.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.